242 related articles for article (PubMed ID: 30206735)
1. Roles of SIRT1/FoxO1/SREBP-1 in the development of progestin resistance in endometrial cancer.
Wang Y; Zhang L; Che X; Li W; Liu Z; Jiang J
Arch Gynecol Obstet; 2018 Nov; 298(5):961-969. PubMed ID: 30206735
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor signaling enhanced by long-term medroxyprogesterone acetate treatment in endometrial carcinoma.
Zhao S; Chen X; Lu X; Yu Y; Feng Y
Gynecol Oncol; 2007 Apr; 105(1):45-54. PubMed ID: 17240435
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor signaling pathway involved in progestin-resistance of human endometrial carcinoma: In a mouse model.
Xu Y; Tong J; Ai Z; Wang J; Teng Y
J Obstet Gynaecol Res; 2012 Dec; 38(12):1358-66. PubMed ID: 22612393
[TBL] [Abstract][Full Text] [Related]
4. Overexpressed epidermal growth factor receptor (EGFR)-induced progestin insensitivity in human endometrial carcinoma cells by the EGFR/mitogen-activated protein kinase signaling pathway.
Ai Z; Wang J; Wang Y; Lu L; Tong J; Teng Y
Cancer; 2010 Aug; 116(15):3603-13. PubMed ID: 20564127
[TBL] [Abstract][Full Text] [Related]
5. The PRB-dependent FOXO1/IGFBP-1 axis is essential for progestin to inhibit endometrial epithelial growth.
Nakamura M; Takakura M; Fujii R; Maida Y; Bono Y; Mizumoto Y; Zhang X; Kiyono T; Kyo S
Cancer Lett; 2013 Aug; 336(1):68-75. PubMed ID: 23603247
[TBL] [Abstract][Full Text] [Related]
6. [Influence of long-term treatment with MPA on the biological character of endometrial carcinoma Ishikawa cell].
Zhao SJ; Chen XJ; Feng YJ
Fen Zi Xi Bao Sheng Wu Xue Bao; 2007 Apr; 40(2):103-12. PubMed ID: 17580663
[TBL] [Abstract][Full Text] [Related]
7. The regulation and function of the forkhead transcription factor, Forkhead box O1, is dependent on the progesterone receptor in endometrial carcinoma.
Ward EC; Hoekstra AV; Blok LJ; Hanifi-Moghaddam P; Lurain JR; Singh DK; Buttin BM; Schink JC; Kim JJ
Endocrinology; 2008 Apr; 149(4):1942-50. PubMed ID: 18096667
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer.
Gu C; Zhang Z; Yu Y; Liu Y; Zhao F; Yin L; Feng Y; Chen X
Cancer Sci; 2011 Mar; 102(3):557-64. PubMed ID: 21205080
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.
Reyes HD; Carlson MJ; Devor EJ; Zhang Y; Thiel KW; Samuelson MI; McDonald M; Yang S; Stephan JM; Savage EC; Dai D; Goodheart MJ; Leslie KK
Gynecol Oncol; 2016 Jan; 140(1):152-60. PubMed ID: 26524723
[TBL] [Abstract][Full Text] [Related]
10. Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells.
Diep CH; Charles NJ; Gilks CB; Kalloger SE; Argenta PA; Lange CA
Cell Cycle; 2013 May; 12(9):1433-49. PubMed ID: 23574718
[TBL] [Abstract][Full Text] [Related]
11. Sterol regulatory element-binding protein-1/fatty acid synthase involvement in proliferation inhibition and apoptosis promotion induced by progesterone in endometrial cancer.
Qiu C; Dongol S; Lv QT; Gao X; Jiang J
Int J Gynecol Cancer; 2013 Nov; 23(9):1629-34. PubMed ID: 24105476
[TBL] [Abstract][Full Text] [Related]
12. [Effect and regulation of metformin on endometrial carcinoma subline of progestin-resistance].
Niu YJ; Shi HR; Xie Y
Zhonghua Fu Chan Ke Za Zhi; 2016 Feb; 51(2):135-40. PubMed ID: 26917483
[TBL] [Abstract][Full Text] [Related]
13. Forkhead transcription factor FOXO1 is a direct target of progestin to inhibit endometrial epithelial cell growth.
Kyo S; Sakaguchi J; Kiyono T; Shimizu Y; Maida Y; Mizumoto Y; Mori N; Nakamura M; Takakura M; Miyake K; Sakamoto M; Inoue M
Clin Cancer Res; 2011 Feb; 17(3):525-37. PubMed ID: 21131554
[TBL] [Abstract][Full Text] [Related]
14. Progestin treatment decreases CD133+ cancer stem cell populations in endometrial cancer.
Guy MS; Qamar L; Behbakht K; Post MD; Sheeder J; Sartorius CA; Spillman MA
Gynecol Oncol; 2016 Mar; 140(3):518-26. PubMed ID: 26731726
[TBL] [Abstract][Full Text] [Related]
15. Medroxyprogesterone acetate causes the alterations of endoplasmic reticulum related mRNAs and lncRNAs in endometrial cancer cells.
Cao W; Gao W; Zheng P; Sun X; Wang L
BMC Med Genomics; 2019 Nov; 12(1):163. PubMed ID: 31718641
[TBL] [Abstract][Full Text] [Related]
16. Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia.
Zhang H; Yan L; Bai Y; Li C; Guo Q; Wang C; Zhao X; Li M
Gynecol Oncol; 2015 Mar; 136(3):549-53. PubMed ID: 25451692
[TBL] [Abstract][Full Text] [Related]
17. Active FOXO1 Is a Key Determinant of Isoform-Specific Progesterone Receptor Transactivation and Senescence Programming.
Diep CH; Knutson TP; Lange CA
Mol Cancer Res; 2016 Feb; 14(2):141-62. PubMed ID: 26577046
[TBL] [Abstract][Full Text] [Related]
18. NrCAM secreted by endometrial stromal cells enhances the progestin sensitivity of endometrial cancer cells through epigenetic modulation of PRB.
Cheng Y; Xie L; Xu Z; Hao M; Yang B; Shan W; Wang Y; Lv Q; Chen X
Cancer Gene Ther; 2022 Oct; 29(10):1452-1462. PubMed ID: 35388173
[TBL] [Abstract][Full Text] [Related]
19. DACH1 suppresses epithelial to mesenchymal transition (EMT) through Notch1 pathway and reverses progestin resistance in endometrial carcinoma.
Zhou Q; Li W; Kong D; Liu Z; Shi Z; Ma X; Li Y; Jiang J
Cancer Med; 2019 Aug; 8(9):4380-4388. PubMed ID: 31215145
[TBL] [Abstract][Full Text] [Related]
20. RNA-seq and ATAC-seq analysis of CD163
Wang L; Lv Q; Wu P; Luo S; Liu S; Chen X; Luo X
Cancer Med; 2023 Mar; 12(5):5964-5978. PubMed ID: 36373483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
